# Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

> **NCT00534118** · NA · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 39 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** donor lymphocytes

## Key facts

- **NCT ID:** NCT00534118
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10-01
- **Primary completion:** 2018-07-26
- **Final completion:** 2018-07-26
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00534118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00534118, "Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00534118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*